Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amarin Corporation plc (ADR) (AMRN), AstraZeneca plc (ADR) (AZN): Right Drug Class, Wrong Company

Page 1 of 2

We’ve been speculating for almost a year that Amarin Corporation plc (ADR) (NASDAQ:AMRN) would be purchased by AstraZeneca plc (ADR) (NYSE:AZN). The large pharma sells cholesterol-lowering drug Crestor, which would be a perfect fit with Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s lipid-lowering fish oil Vascepa.

Right drug class. Wrong company.

AstraZeneca plc (ADR)Instead, AstraZeneca plc (ADR) (NYSE:AZN) purchased Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s competitor Omthera Pharmaceuticals Inc (NASDAQ:OMTH), which has a fish oil product, Epanova, similar to Vascepa. Omthera Pharmaceuticals Inc (NASDAQ:OMTH) expects to file a marketing application with the Food and Drug Administration within a few months for the same indication that Vascepa is currently approved for.

Why Omthera over Amarin Corporation plc (ADR) (NASDAQ:AMRN)? Here are three possibilities:

Technology

Omthera’s technology allows for better absorption, which allows for once-daily dosing without food. Vascepa is taken twice a day with food. It may not seem like a lot, but patients prefer the more convenient dosing, and when all things are equal, doctors will prescribe the once-daily drug because they know they’ll get better adherence from the patient.

Patents

Without being able to patent the fish oil itself — a composition-of-matter patent — Amarin Corporation plc (ADR) (NASDAQ:AMRN) and Omthera have to rely on patents on how their drugs are made. I’m not a patent lawyer nor do I play one on the Internet, but a formulation that changes the dosing might be more defendable than Amarin’s war chest of patents. We’ll know in a few years when the generic-drug vultures to come in.

Price

This seems like the most obvious reason. Amarin ended last week with a market cap around $1 billion. AstaZeneca is paying about $323 million for Omthera and could give shareholders an additional $120 million in development and sales milestone payments.

With an approved drug and an outcomes study well under way, Amarin is arguably worth more than Omthera, but there’s a long way between $443 million and $1 billion. Amarin’s shares are rightfully seeing pressure today as they adjust to the reality check on what big pharma is willing to pay.

Poor Amarin?

Don’t feel too sorry for the company. Vascepa still has a solid head start and could have an expanded approval for patients with moderately high triglyceride levels by the end of the year — before Epanova is even approved for patients with extremely high triglyceride levels.

At this point, I doubt Amarin gets a buyout above $1 billion. A more likely scenario is finding a partner willing to market Vascepa that might make a purchase down the line. Amarin is clearly worth more than $1 billion if doctors will prescribe Vascepa for moderately high triglyceride levels, but they may not do that in large numbers until the outcomes study proves that Vascepa decreases heart attacks and strokes.

Page 1 of 2
Loading Comments...